GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncimmune Holdings PLC (LSE:ONC) » Definitions » Price-to-Owner-Earnings

Oncimmune Holdings (LSE:ONC) Price-to-Owner-Earnings : 2.98 (As of Jun. 05, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Oncimmune Holdings Price-to-Owner-Earnings?

As of today (2024-06-05), Oncimmune Holdings's share price is £0.1785. Oncimmune Holdings's Owner Earnings per Share (TTM) ended in Aug. 2023 was £0.06. It's Price-to-Owner-Earnings for today is 2.98.


The historical rank and industry rank for Oncimmune Holdings's Price-to-Owner-Earnings or its related term are showing as below:

LSE:ONC' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.45   Med: 3.59   Max: 4.31
Current: 3.08

During the past 12 years, the highest Price-to-Owner-Earnings of Oncimmune Holdings was 4.31. The lowest was 2.45. And the median was 3.59.


LSE:ONC's Price-to-Owner-Earnings is ranked better than
95.76% of 165 companies
in the Biotechnology industry
Industry Median: 33.78 vs LSE:ONC: 3.08

As of today (2024-06-05), Oncimmune Holdings's share price is £0.1785. Oncimmune Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 was £0.11. Therefore, Oncimmune Holdings's PE Ratio for today is 1.62.

As of today (2024-06-05), Oncimmune Holdings's share price is £0.1785. Oncimmune Holdings's EPS without NRI for the trailing twelve months (TTM) ended in was £0.11. Therefore, Oncimmune Holdings's PE Ratio without NRI for today is 1.62.

During the past 12 years, Oncimmune Holdings's highest PE Ratio without NRI was 8.50. The lowest was 1.79. And the median was 5.96.


Oncimmune Holdings Price-to-Owner-Earnings Historical Data

The historical data trend for Oncimmune Holdings's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncimmune Holdings Price-to-Owner-Earnings Chart

Oncimmune Holdings Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 Aug23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 3.63

Oncimmune Holdings Semi-Annual Data
May14 Nov14 May15 Nov15 May16 Nov16 May17 Nov17 May18 Nov18 May19 Nov19 May20 Nov20 May21 Nov21 May22 Feb23 Aug23 Feb24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 3.63 -

Competitive Comparison of Oncimmune Holdings's Price-to-Owner-Earnings

For the Biotechnology subindustry, Oncimmune Holdings's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncimmune Holdings's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncimmune Holdings's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Oncimmune Holdings's Price-to-Owner-Earnings falls into.



Oncimmune Holdings Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Oncimmune Holdings's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.1785/0.06
=2.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncimmune Holdings  (LSE:ONC) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Oncimmune Holdings Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Oncimmune Holdings's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncimmune Holdings (LSE:ONC) Business Description

Traded in Other Exchanges
Address
1 Park Row, MediCity - D6 Building, Leeds, GBR, LS1 5AB
Oncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacture, and commercialization of personalized immunodiagnostics for the screening, detection and care of cancer. The company's operating segment includes Early CDT Lung and ImmunoINSIGHTS.

Oncimmune Holdings (LSE:ONC) Headlines

No Headlines